Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAD106 in Mild Alzheimer's Disease
NCT01097096Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2010
- Primary completion
- Dec 2012
- Countries
- 10
01
Overview
A Phase 2 trial of amilomotide in Alzheimer's disease (AD), sponsored by Novartis. Started Mar 2010; status: completed.
02
Drugs
amilomotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01097096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01097096.